The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement

Thrombosis Research

Volumn 132, Issue 6, 2013, Pages 685-691

  Gionis, Michalis N ^a   Ioannou, Christos V ^a   Katsamouris, Asterios N ^b   Katonis, Pavlos ^a   Balalis, Konstantinos ^a   Sfyridaki, Katerina ^c   Elalamy, Ismail ^d,e   Gerotziafas, Grigoris T ^d,e  

^a UNIVERSITY OF CRETE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Venizelion General Hospital   (Greece)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL TENON   (France)

Author keywords

Low Molecular Weight Heparin; Orthopaedic surgery; Thrombin generation; Thromboproprhylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; THROMBIN;

AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPERATION DURATION; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTE POOR PLASMA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ENDOGENOUS THROMBIN POTENTIAL; ETP; LMWHS; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARINS; MEAN RATE INDEX; MRI; ORTHOPAEDIC SURGERY; THR; THROMBIN GENERATION; THROMBOPROPRHYLAXIS; TIME NECESSARY TO PEAK; TKR; TOTAL HIP REPLACEMENT; TOTAL KNEE REPLACEMENT; TT-PEAK; VENOUS THROMBOEMBOLISM; VTE;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 84889881792     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.09.037     Document Type: Article

References (43)

1. J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, and H.J. Schünemann Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6-Suppl. 2008 1105 1125
2. G.H. Guyatt, E.A. Akl, M. Crowther, D.D. Gutterman, and H.J. Schuünemann American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel-Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2-Suppl. 2012 7S 47S
3. H.C. Hemker, and S. Béguin Mode of action of unfractioned and low molecular weight heparins on the generation of thrombin in plasma Haemostasis 20 Suppl. 1 1990 81 92
4. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar for the RECORD1 Study Group. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty N Engl J Med 358 2008 2765 2775
5. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
6. M.R. Lassen, W. Ageno, and L.C. Borris for the RECORD3 investigators. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty N Engl J Med 358 2008 2776 2786
7. G.T. Gerotziafas, A.D. Petropoulou, E. Verdy, M.M. Samama, and I. Elalamy Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation J Thromb Haemost 5 2007 955 962
8. M.M. Samama, L. Bara, and G.T. Gerotziafas Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs) Haemostasis 24 1994 105 117
9. S. Beguin, J. Mardiguian, T. Lindhout, and H.C. Hemker The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma Thromb Haemost 61 1989 30 34
10. S. Beguin, and H.C. Hemker Mode of action of enoxaparin in plasma Acta Chir Scand Suppl 556 1990 51 56
11. G.T. Gerotziafas, A. Zafiropoulos, P. Van Dreden, E. Karavaggeli, N. Goutzoumas, and P. Nikolaidis Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina Br J Haematol 120 2003 611 617
12. V. Martinez-Sales, V. Vila, E. Réganon, J.G. Oms, and J. Aznar Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells Haematologica 88 2003 694 699
13. P.M. Sandset, B. Bendz, and J.B. Hansen Physiological function of tissue factor pathway inhibitor and interaction with heparins Haemostasis 30 Suppl. 2 2000 48 56
14. P. Schoen, T. Lindhout, J. Franssen, and H.C. Hemker Low molecular weight heparin-catalyzed inactivation of factor antithrombin III-effect of platelet factor 4 Thromb Haemost 66 1991 435 441
15. K. Kageyama, Y. Nakajima, M. Shibasaki, S. Hashimoto, and T. Mizobe Increased platelet, leucocyte and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty J Thromb Haemost 5 2007 738 745
16. L. Bara, A. Planes, and M.M. Samama Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery Br J Haematol 104 1999 230 240
17. E.M. Antman, C.H. McCabe, E.P. Gurfinkel, A.G.G. Turpie, P.J.L.M. Bennink, and D. Salein Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Circulation 100 1999 1593 1601
18. M.J. Ma, C.A. Jackevicius, and E. Yeo Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease Ann Pharmacother 38 2004 1576 1581
19. A.V. Bendetowicz, H. Kai, R. Knebel, H. Caplain, H.C. Hemker, and T. Lindhout The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma-a study in human volunteers Thromb Haemost 72 1994 705 712
20. Y. Falck-Ytter, C.W. Francis, N.A. Johanson, C. Curley, O.E. Dahl, and S. Schulman Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 Feb e278S e325S 10.1378/chest.11-2404
21. M.C. Struijk-Mulder, H.B. Ettema, C.C. Verheyen, and H.R. Buller Comparing consensus guidelines thromboprophylaxis in orthopedic surgery J Thromb Haemost 8 2010 678 683
22. American Academy of Orthopaedic Surgeons Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty Evidence-based guideline and evidence report 2011 79 [Available at: http://www.aaos.org/research/guidelines/VTE/VTE-full-guideline.pdf. Accessed May 2, 2013]
23. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, and Union Internationale de Phlebologie Prevention and treatment of venous thromboembolism. International Consensus Statements (guidelines according to scientific evidence) Int Angiol 25 2006 101 161
24. National Institute for Health and Clinical Excellence Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. This guideline updates NICE clinical guideline 46 and replaces it. London 2010 24 27 [Available at: http://www.nice.org.uk/ nicemedia/live/12695/47195/47195.pdf.]
25. Scottish Intercollegiate Guidelines Network Prophylaxis of venous thromboembolism. SIGN guideline No 62 [Internet] 2002 51 [Edimburgh]
26. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (Germany) Stationare und ambulante Thromboembolie - Prophylaxe in der Chirurgie und der perioperativen Medizin [Internet] 2003 12
27. F.H.A. Maffei, J.S. Caiafa, E. Ramacciotti, A.A.L. Castro Grupo de Elaboracao de Normas de Orientacao Clinica em Thrombose Venosa Profunda da SBACV Normas de orientacao venosa profunda (revisao). (Brazil) 2005 16 [Internet]
28. Southern Africa Society of Thrombosis and Haemostasis Guideline for prophylactic anticoagulation S Afr Med J 94 2004 691 695
29. T. Kobayashi, M. Nakamura, M. Sakuma, N. Yamada, M. Sakon, and S. Fujita Incidence of pulmonary thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan Clin Hemorheol Microcirc 35 2006 257 259
30. C.M. Samama, P. Albaladejo, D. Benhamon, M. Bertin - Maghit, N. Bruder, and J.D. Doublet Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines Eur J Anaesthesiol 23 2006 95 116
31. The Australia and New Zealand working party on the Management and Prevention of Venous Thromboembolism Prevention of Venous Thromboembolism [Internet]. Australia: Health Education and Management Innovations 2007 20
32. J.W. Eikelboom, G. Karthikeyan, N. Fagel, and J. Hirsh for the American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ: What Are the Implications for Clinicians and Patients? Chest 135 2009 513 520
33. G.H. Westrich, F. Bottner, R.E. Windsor, R.S. Laskin, S.B. Haas, and T.P. Sculco VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty J Arthroplasty 21 2006 139 143
34. H.V. Ioannou, M. Mitsis, A. Eleftheriou, M. Matsagas, V. Nousias, and C. Rigopoulos The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece Int Angiol 19 2000 314 318
35. C.G. Zalavras, S. Giotopoulou, E. Dokou, M. Mitsis, H.V. Ioannou, and C. Tsaousi Prevalence of the G20210A prothrombin gene mutation in North-western Greece and association with venous thromboembolism Int Angiol 22 2003 55 57
36. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 2003 4 15
37. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points Chest 126 2004 501 508
38. W. Ageno, A.C. Spyropoulos, and A.G. Turpie Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients Thromb Haemost 107 2012 1027 1034
39. L.C. Borris Barriers to the optimal use of anticoagulants after orthopaedic surgery Arch Orthop Trauma Surg 129 2009 1441 1445
40. R. Altman, A.S. Scazziota, S. Pons, L. Herrera, A.G. Keller, and A.R. Assefi Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity Curr Med Res Opin 27 2011 1 9
41. L. Green, A.S. Lawrie, S. Patel, F. Hossain, A. Chitolie, and I.J. Mackie The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation Br J Haematol 151 2010 469 476
42. R. Al Dieri, S. Alban, S. Béguin, and H.C. Hemker Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight J Thromb Haemost 4 2006 83 89
43. C. Papageorgiou, P. Van Dreden, E. Marret, F. Bonnet, F. Robert, and A. Spyropoulos Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma Thromb Res 132 2013 584 591